DocWire News Editors

DocwireNews

<p>Albiglutide was superior to placebo for the reduction of major adverse cardiac events (MACE) in patients with type 2&nbsp;<a href="https://proddocwire.wpengine.com/tag/diabetic/">diabetes</a>&nbsp;and&nbsp;<a href="https://proddocwire.wpengine.com/tag/cardiovascular-disease/">cardiovascular disease</a>&nbsp;(CVD), new study results indicate.&nbsp;<span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'>&nbsp;</span><p>The authors, publishing in The Lancet, conducted a double-blind, randomized, placebo-controlled study that included 9,463 patients who were randomly&nbsp;assigned&nbsp;(1:1) to either receive albiglutide (n=4,731) or placebo (n=4,732). The primary study outcome was first occurrence of cardiovascular death,&nbsp;<a href="https://proddocwire.wpengine.com/tag/myocardial-infarction/">myocardial infarction</a>, or stroke. Median follow-up was 1.6 years.&nbsp;<span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'>&nbsp;</span></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Presenting now at <a href="https://twitter.com/hashtag/EASD2018?src=hash&amp;ref_src=twsrc%5Etfw">#EASD2018</a>: Albiglutide and cardiovascular outcomes in patients with<br>type 2 <a href="https://twitter.com/hashtag/diabetes?src=hash&amp;ref_src=twsrc%5Etfw">#diabetes</a> and <a href="https://twitter.com/hashtag/cardiovascular?src=hash&amp;ref_src=twsrc%5Etfw">#cardiovascular</a> disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial <a href="https://t.co/w6nUsgvK51">https://t.co/w6nUsgvK51</a> <a href="https://t.co/Q1FRKU5ExZ">pic.twitter.com/Q1FRKU5ExZ</a></p>
<p>&mdash; The Lancet (@TheLancet) <a href="https://twitter.com/TheLancet/status/1047064902710497287?ref_src=twsrc%5Etfw">October 2, 2018</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>According to the results, there were 611 total&nbsp;occurrences&nbsp;of the&nbsp;primary&nbsp;endpoint (338 of 4,731 [7%] in the albiglutide group versus 428 of 4,732 [9%] patients in the placebo group; HR=0.78, 95% CI, 0.68 to 0.90; P&lt;0.0001 for noninferiority; P=0.0006 for superiority), indicating superiority for albiglutide.&nbsp;Pancreatitis,&nbsp;pancreatic&nbsp;cancer, medullary thyroid carcinoma, and other serious adverse events were not different between study groups.<span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'>&nbsp;</span></p><p>&ldquo;In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events,&rdquo; the researchers wrote in their&nbsp;aabstract. &ldquo;Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes.&rdquo;<span data-ccp-props='{"201341983":0,"335559739":160,"335559740":259}'>&nbsp;</span></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Harmony Outcomes RCT for diabetic patients with CV disease in 28 (!!!) countries. Albiglutide arm showed reduced MACE events showing GLP-1 receptor agonists may be helpful in treating this patient population. @UMKCBioMed <a href="https://twitter.com/hashtag/UMKCClinTrial?src=hash&amp;ref_src=twsrc%5Etfw">#UMKCClinTrial</a> <a href="https://t.co/GKyhyvFAgZ">https://t.co/GKyhyvFAgZ</a></p>
<p>&mdash; Jeremy Provance, PhD (@jeremyprovance) <a href="https://twitter.com/jeremyprovance/status/1047112415073247232?ref_src=twsrc%5Etfw">October 2, 2018</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Adding more HARMONY to the cardiovascular protection story for GLP-1R agonists in Type 2 Diabetes with CVD, albiglutude reduces MACE &#8294; <a href="https://t.co/dw5zA7EEHv">https://t.co/dw5zA7EEHv</a></p>
<p>&mdash; Julie A. Lovshin (@JulieALovshin) <a href="https://twitter.com/JulieALovshin/status/1047081361301893120?ref_src=twsrc%5Etfw">October 2, 2018</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Albiglutide was SUPERIOR to PLACEBO with respect to MACE: Albiglutide &amp; CC outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial <a href="https://t.co/A1LRKlG5gp">https://t.co/A1LRKlG5gp</a> <a href="https://twitter.com/EASDnews?ref_src=twsrc%5Etfw">@EASDnews</a> <a href="https://twitter.com/hashtag/EASD2018?src=hash&amp;ref_src=twsrc%5Etfw">#EASD2018</a> <a href="https://twitter.com/hashtag/HARMONY?src=hash&amp;ref_src=twsrc%5Etfw">#HARMONY</a> <a href="https://t.co/IyeSn3StGU">pic.twitter.com/IyeSn3StGU</a></p>
<p>&mdash; James Boyle (@drjamesboyle) <a href="https://twitter.com/drjamesboyle/status/1047068995122278400?ref_src=twsrc%5Etfw">October 2, 2018</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<p lang="en" dir="ltr">Another GLP1 analog reaches its primary endpoint.Worth of note, curves start separating after 1 yr, no CV death reduction (short duration?). No difference in body weight or SBP (?). However, may support rhe notion that benefits are not due to low BP or weight loss.<a href="https://twitter.com/hashtag/cardiotwitter?src=hash&amp;ref_src=twsrc%5Etfw">#cardiotwitter</a> <a href="https://t.co/YELnKaAXen">https://t.co/YELnKaAXen</a></p>
<p>&mdash; Sergio Kaiser MD, PhD, FACC, FESC &#127463;&#127479;&#127470;&#127473;&#127479;&#127476;&#127482;&#127462; (@pabeda1) <a href="https://twitter.com/pabeda1/status/1047073546894237700?ref_src=twsrc%5Etfw">October 2, 2018</a></p>
</blockquote><p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p><p>Source: <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32261-X/fulltext?utm_campaign=lancet&amp;utm_content=77774558&amp;utm_medium=social&amp;utm_source=twitter">The Lancet</a></p></p>


MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Albiglutide Bests Placebo for Prevention of MACE in Type 2 Diabetic Patients with CVD

Cardiology

Albiglutide was superior to placebo for the reduction of major adverse cardiac events (MACE) in patients with type 2 diabetes and cardiovascular disease (CVD), new study ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe